SÖDERTÄLJE, Sweden, June 11, 2026
Anocca AB announced the successful dosing of the first patients in its VIDAR-1 clinical program evaluating ANOC-001, a precision T cell receptor-modified T cell therapy (TCR-T) targeting KRAS G12V-mutated pancreatic ductal adenocarcinoma (PDAC). The milestone marks the first clinical deployment of Anocca’s proprietary non-viral gene-edited T-cell therapy platform and represents a significant advancement in the development of personalized immunotherapies for one of the deadliest forms of cancer. The Phase I study is currently enrolling patients across multiple clinical sites in Sweden, Denmark, Germany, and the Netherlands.
ANOC-001 Targets KRAS Mutations in Pancreatic Cancer
Anocca’s lead clinical candidate, ANOC-001, is designed to target tumors carrying the KRAS G12V mutation, one of the most common genetic alterations associated with pancreatic cancer. The therapy utilizes engineered T cells capable of recognizing and attacking cancer cells expressing the mutant KRAS protein. Pancreatic ductal adenocarcinoma remains one of the most aggressive malignancies, with a five-year survival rate below 10% and limited treatment options available for patients with advanced disease. By redirecting the immune system against a well-established cancer-driving mutation, Anocca aims to address a significant unmet medical need in oncology.
Non-Viral Gene Editing Platform Advances Precision Cell Therapy
The company highlighted that ANOC-001 is the first non-viral gene-edited TCR-T cell therapy to be evaluated in Europe, representing a major technological milestone in cell therapy development. Unlike traditional viral vector approaches, Anocca’s non-viral gene-editing technology is designed to improve manufacturing scalability, product consistency, and future commercial feasibility. The therapy was discovered, developed, and manufactured entirely at Anocca’s in-house facilities in Sweden using the company’s proprietary platform for identifying, engineering, and characterizing therapeutic T-cell receptors targeting cancer-specific mutations.
Advertisement
VIDAR-1 Program Designed to Expand KRAS-Targeted Immunotherapy
The VIDAR-1 Phase I clinical trial has been structured to evaluate multiple TCR-T product candidates targeting different KRAS mutations and HLA combinations, enabling broader patient coverage across several cancer types. While ANOC-001 is the first therapy to enter the study, Anocca plans to introduce additional candidates targeting other KRAS variants, including mutations commonly found in pancreatic, colorectal, and lung cancers. Recruitment and manufacturing activities remain ongoing as the company advances the multi-center trial across eight leading university hospitals in Europe. The successful dosing of the first patients marks an important step toward validating precision TCR-T therapies as a new treatment approach for patients with advanced KRAS-driven cancers.
Anocca Strengthens Position in Advanced Cell Therapy Development
The initiation of patient dosing demonstrates Anocca’s capability to independently discover, manufacture, and clinically deploy advanced cellular immunotherapies. The company believes its precision TCR-T platform has the potential to enable scalable development of personalized cancer treatments targeting previously difficult-to-drug mutations. As the VIDAR-1 program progresses, clinical data from ANOC-001 and future KRAS-targeted candidates may provide important insights into the effectiveness of engineered T-cell therapies in solid tumors, an area that has historically remained challenging for the cell therapy field.
Source: Anocca, press release
